11. The use of a compound of formula (I) as defined in any one of claims 1 to 10 in the manufacture of a medicament for the treatment of a disease or condition treatable by modulating activity against the CXCR7 receptor.

12. Use of an agent in the manufacture of a medicament for treating a disease or condition treatable by modulating activity against the CXCR7 receptor comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) as defined in any one of claims 1 to 10 in said agent.

13. The use according to claim 11 or the use according to claim 12, wherein the disease or condition is treatable by interfering selectively with the natural activity of the CXCR7 receptor and its natural ligands CXCL11 and/or CXCL12.

14. The use of a compound of formula (I) as defined in any one of claims 1 to 10 in the manufacture of a medicament for the treatment, prevention or the supportive treatment of a disease or condition related to the activity of CXCR7 selected from dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and oncology, or the mobilisation of stem cells.

15. Use of an agent in the manufacture of a medicament for the treatment, prevention or the supportive treatment of a disease or condition related to the activity of CXCR7 selected from dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and oncology, or the mobilisation of stem cells comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) in said agent as defined in any one of claims 1 to 10.

16. The use according to claim 14 or the use according to claim 15, wherein the disease or condition related to the activity of CXCR7 is selected from HIV infections, Epstein-Barr Virus infection; Type I and or Type II diabetes mellitus; conjunctivitis, scleritis, uveitis, rhinosinusitis, Whim syndrome, lupus erythematosus, osteoarthritis, rheumatoid arthritis, synovitis, psoriasis, multiple sclerosis, Crohns disease, inflammatory bowl disease, mixed connective tissue disease, chronic lymphocytic thyroiditis, Graves' disease, graft-versus-host disease, Sjögren's syndrome; dry eye syndrome, glaucoma, age-related macular

degeneration; pulmonary arterial hypertension, pulmonary hypoxia, atherosclerosis, myocarditis, heart failure including myocardial infarction, arterial thrombosis, strike and angiogenesis; chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, asthma; sarcomaincluding asteosarcoma, rhabdomyosarcoma, Kaposi's sarcoma and synoovial sarcoma; lipoma including angiolipoma; glioblastoma multiforme, astrocytomas, neuroblastoma; carcinoma including adenocarcinoma; malignant epithelial and mucoepidermoid neoplasms, thyroid neoplasm, gonadal neoplasms, prostate cancer, breast cancer, melanoma, lung carcinoma, pancreatic carcinoma, colorectal cancer; solid tumors; lymphoma including Birkitt's lymphoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma; multiple myeloma and leukemia; and metastasis.

17. Use of a compound of formula (I) as defined in any one of claims 1 to 10, in the manufacture of a medicament for the inhibition of neointima formation; stem cell mobilisation of peripheral blood stem cells and/or mesenchymal stem cells; mobilisation of endothelial or neuronal progenitor cells; or tissue-repair in human or other mammals.

18. Use of an agent in the manufacture of a medicament for inhibiting neointima formation; mobilising peripheral blood stem cells and/or mesenchymal stem cells, endothelial or neuronal progenitor cells; or tissue repair, in a human or other mammal, comprising administering an effective amount of a compound of formula (I) in said agent as defined in any one of claims 1 to 10, to a subject in need thereof.

19. The use according to any one of the preceding claims, or the method according to any one of claims 2 to 10, 12, 13, 15, 16 or 18, wherein the medicament is in a form suitable for, or the administration is, oral, topical, transdermal, injection, buccal, transmucosal, rectal, pulmonary or inhalation administration.

20. The use according to claim 19, wherein the medicament is in the form of a tablet, a dragee, a capsule, a solution, a liquid, a gel, a plaster, a cream, an ointment, a syrup, a slurry, a suspension, a spray, a nebuliser or a suppository.

21. The use according to any one of claims 1, or 3 to 11, 13, 14, 16 or 17, wherein the medicament is adapted to administer the compound of formula (I) as the sole active pharmaceutical ingredient or in combination with one or more other active pharmaceutical ingredients present in the medicament or in another medicament.